Drug Profile
Research programme: cancer vaccines - Colby
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Juvaris BioTherapeutics
- Class
- Mechanism of Action Immunostimulants; Toll-like receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; Glioblastoma
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral, Injection)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Glioblastoma in USA (Parenteral, Injection)
- 10 Sep 2011 This cancer vaccine research programme is licensed to Colby Pharmaceutical Company worldwide